Wockhardt shares bounce back 4% after two-day slump

Wockhardt shares on December 1 jumped 19% after the US FDA accepted the company’s New Drug Application for Zaynich, its first-in-class antibiotic. But the rally cooled over the next two days as investors booked profits, leading to back-to-back 5% drops.